Keros Therapeutics, Inc. (KROS)
KROS Stock Price Chart
Explore Keros Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze KROS price movements and trends.
KROS Company Profile
Discover essential business fundamentals and corporate details for Keros Therapeutics, Inc. (KROS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Apr 2020
Employees
163.00
Website
https://www.kerostx.comCEO
Jasbir S. Seehra
Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
KROS Financial Timeline
Browse a chronological timeline of Keros Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 24 Feb 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is -$1.11, while revenue estimate is $4.22M.
Earnings released on 6 Aug 2025
EPS came in at -$0.76 surpassing the estimated -$1.14 by +33.33%, while revenue for the quarter reached $18.17M , beating expectations by +465.88%.
Earnings released on 6 May 2025
EPS came in at $3.62 surpassing the estimated -$0.01 by +36.30K%, while revenue for the quarter reached $211.25M , beating expectations by +272.93%.
Earnings released on 26 Feb 2025
EPS came in at -$1.14 surpassing the estimated -$1.36 by +16.18%, while revenue for the quarter reached $3.04M , missing expectations by -86.32%.
Earnings released on 6 Nov 2024
EPS came in at -$1.41 falling short of the estimated -$1.26 by -11.90%, while revenue for the quarter reached $388.00K , missing expectations by -83.20%.
Earnings released on 7 Aug 2024
EPS came in at -$1.25 falling short of the estimated -$1.23 by -1.63%, while revenue for the quarter reached $37.00K .
Earnings released on 8 May 2024
EPS came in at -$1.21 surpassing the estimated -$1.31 by +7.63%, while revenue for the quarter reached $83.00K .
Earnings released on 28 Feb 2024
EPS came in at -$1.34 surpassing the estimated -$1.38 by +2.90%, while revenue for the quarter reached $143.00K .
Earnings released on 6 Nov 2023
EPS came in at -$1.33 surpassing the estimated -$1.34 by +0.75%, while revenue for the quarter reached $8.00K .
Earnings released on 7 Aug 2023
EPS came in at -$1.27 surpassing the estimated -$1.34 by +5.22%.
Earnings released on 4 May 2023
EPS came in at -$1.26 falling short of the estimated -$1.13 by -11.50%.
Earnings released on 3 Mar 2023
EPS came in at -$1.09 surpassing the estimated -$1.12 by +2.68%.
Earnings released on 3 Nov 2022
EPS came in at -$0.92 surpassing the estimated -$1.26 by +26.98%.
Earnings released on 4 Aug 2022
EPS came in at -$1.13 falling short of the estimated -$1.07 by -5.61%, while revenue for the quarter reached $100.00K .
Earnings released on 5 May 2022
EPS came in at -$1.01 falling short of the estimated -$0.86 by -17.44%.
Earnings released on 9 Mar 2022
EPS came in at -$0.30 surpassing the estimated -$0.94 by +68.09%, while revenue for the quarter reached $20.00M .
Earnings released on 4 Nov 2021
EPS came in at -$0.87 falling short of the estimated -$0.72 by -20.83%.
Earnings released on 5 Aug 2021
EPS came in at -$0.67 falling short of the estimated -$0.66 by -1.52%, while revenue for the quarter reached $100.00K , meeting expectations.
Earnings released on 6 May 2021
EPS came in at -$0.68 falling short of the estimated -$0.58 by -17.24%.
Earnings released on 25 Mar 2021
EPS came in at -$0.49 surpassing the estimated -$0.57 by +14.04%.
Earnings released on 10 Nov 2020
EPS came in at -$0.60 falling short of the estimated -$0.58 by -3.45%, while revenue for the quarter reached $2.50M .
KROS Stock Performance
Access detailed KROS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.